A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. Doctors share what patients should know about the drug.
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...
This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...